Dyskinesia Dialogue Starter

Getting the dyskinesia conversation going

Dyskinesia Dialogue Starter

Dyskinesia Dialogue Starter

Getting the dyskinesia conversation going

Managing dyskinesia and off time begins with a discussion among you, your patient, and their care partner.

Your patients may be more comfortable talking about OFF time than dyskinesia. Dyskinesia, however, continues to impact their daily lives. Keep in mind that your patients may:

  • Downplay their dyskinesia to avoid OFF time
  • Not realize the impact of their dyskinesia or OFF time
  • Believe dyskinesia is just a sign of disease progression
  • Assume there are no dyskinesia treatment options

Your patients may not always be forthcoming about the difficulties they face with dyskinesia and OFF time. There are many reasons for this behavior. For instance, they may fear the need to resort to a lower levodopa dose.

The following may indicate that your patients struggle with dyskinesia and OFF time:

  • They make comments that imply compromise or settling
  • Describing unpredictable episodes of dyskinesia, ON, and OFF time
  • Referring to ON time negatively
  • An increase in "accident prone" behaviors
  • Difficulties with activities or hobbies
  • Feeling embarrassed in social situations
  • Care partner makes comments about movement control
  • Difficulties at work

Based on learnings from leading organizations, including The Michael J. Fox Foundation and Parkinson’s Foundation.

GOCOVRI Onboard®: Dedicated to helping your patients access GOCOVRI®

Designed to improve the specialty pharmacy experience with a direct line of contact through your GOCOVRI® Care Coordinator

Your GOCOVRI® Care Coordinator is a dedicated, single point-of-contact for you and your patients who partners with a specialty pharmacy to provide timely fulfillment.

In addition, GOCOVRI Onboard® offers:

  • Benefits verification
  • Electronic submission of prior authorizations through CoverMyMeds®
  • Next-day delivery to patients each month
  • Monthly follow-up from a specialty pharmacy to schedule deliveries to patients
  • Answers to questions you or your patients may have
GOCOVRI Onboard® Logo
8 am - 8 pm ET M-F

See how GOCOVRI Onboard® can HELP YOUR PATIENTS ACCESS GOCOVRI®

93%

 approved

Regardless of formulary status, 93% of prescriptions have been processed and approved*

pay 

$25

 OR LESS

For patients receiving GOCOVRI®, ~75% pay $25 or less per prescription and ~92% pay $100 or less*

$20

 CO-PAY

Commercially insured patients who participate in the GOCOVRI® Co-pay Assistance Program pay $20 per prescription

Once you have identified an appropriate patient, a free 4-week trial may be available

* Based on specialty pharmacy data 1/1/2019-6/30/2019.
This offer is valid only for patients who have commercial (nongovernment-funded) insurance and must meet eligibility requirements. See full Terms & Conditions.
For new, eligible patients.

5 easy steps to get patients started with GOCOVRI Onboard®

Fill Out Prescription Form, Icon

STEP 1

FILL OUT, COLLECT SIGNATURES, AND FAX THE PRESCRIPTION FORM TO GOCOVRI Onboard® AT 1-844-826-7626
Be sure to complete the Prescription Form before your patient leaves the office

Benefits Verification, Icon

STEP 2

A BENEFITS VERIFICATION IS INITIATED

GOCOVRI Onboard® Logo

STEP 3

IF A PRIOR AUTHORIZATION (PA) IS REQUIRED, GOCOVRI Onboard® WILL INITIATE THE PA AND SEND TO YOUR OFFICE VIA CoverMyMeds®. GOCOVRI Onboard® may reach out to you to ensure timely completion

Specialty Pharmacy, Icon

STEP 4

THE SPECIALTY PHARMACY WILL CALL YOUR PATIENT TO SCHEDULE NEXT-DAY DELIVERY OF GOCOVRI®
Note: your patients will need to speak with the specialty pharmacy over the phone in order to schedule their first delivery. If the specialty pharmacy is not able to reach the patient, they may reach out to you to help facilitate contact

Specialty Pharmacy Scheduling Deliveries, Icon

STEP 5

THE SPECIALTY PHARMACY WILL FOLLOW UP MONTHLY TO SCHEDULE RECURRING DELIVERIES

Programs that offer clinical experience

Free 4-week trial

This program provides your new, eligible patients with a 4-week supply of GOCOVRI®. No purchase is required for your patients to participate.

GOCOVRI® Packaging

In-office samples

GOCOVRI® samples are offered to provide you and your patients with the clinical experience to determine if GOCOVRI® is the right next step in their treatment regimen.

Patients may either participate in the free-trial program or the in-office sample program, but not both. Additionally, these programs are only available for patients who are new to treatment and trying GOCOVRI® for its on-label indication.

Contact your local GOCOVRI® representative to learn more. You may also request a representative now.

No purchase of GOCOVRI® or enrollment into GOCOVRI Onboard® is required. See full Terms & Conditions.

GOCOVRI® Packaging

Downloadable resources

INDICATION and important safety information

GOCOVRI® (amantadine) extended release capsules is indicated:

  • For the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
  • As adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes

It is not known if GOCOVRI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2.

WARNINGS AND PRECAUTIONS

Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

ADVERSE REACTIONS
The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

View the full Prescribing Information.